Can-Fite BioPharma Ltd.

TASE:CANF Stock Report

Market Cap: ₪36.8m

Can-Fite BioPharma Balance Sheet Health

Financial Health criteria checks 5/6

Can-Fite BioPharma has a total shareholder equity of $2.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.9M and $3.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$4.73m
EquityUS$2.48m
Total liabilitiesUS$3.44m
Total assetsUS$5.92m

Recent financial health updates

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

Jun 30
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Mar 08
We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Nov 21
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

May 16
Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Jan 31
We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: CANF's short term assets ($5.8M) exceed its short term liabilities ($2.0M).

Long Term Liabilities: CANF's short term assets ($5.8M) exceed its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: CANF is debt free.

Reducing Debt: CANF has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CANF has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if CANF has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 09:29
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Can-Fite BioPharma Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCG Capital
Jason KolbertD. Boral Capital LLC.
Deepak SonawaneHaitong International Research Limited